OGDH and cancer: OGDH complex dysregulation contributes to increased ROS levels and interrupts substrate fluxes, leading to the production of oncometabolites, such as L-2-hydroxyglutarate, during the process of cancer pathogenesis and development [5,97] (Figure 6).